DISPAIR瘘风险评分:远端胰腺切除术后临床相关胰瘘风险的新工具
本研究基于芬兰和瑞典两家医院668例远端胰腺切除术患者,开发并外部验证了预测临床相关术后胰瘘(CR-POPF)的DISPAIR评分。最终模型包含三个术前变量:横断部位(颈部 vs 体/尾部)、横断处胰腺厚度和糖尿病。内部验证AUROC为0.904,外部验证为0.798。验证队列中定义的低、中、高、极高危组CR-POPF发生率分别为8.7%、22.0%、63%和81%。
要点
- DISPAIR评分仅用三个术前变量预测远端胰腺切除术后CR-POPF。
- 外部验证AUROC为0.798,校准斜率0.719、截距0.192。
- 验证队列高危组CR-POPF发生率达63%,极高危组达81%。
核心结论
- DISPAIR评分可用于远端胰腺切除术后CR-POPF的风险分层,指导临床决策和风险调整后的结局比较。
研究设计与样本
- 回顾性队列研究,纳入芬兰赫尔辛基大学医院2013—2021年和瑞典卡罗林斯卡大学医院2010—2020年行远端胰腺切除术的患者,共668例(赫尔辛基266例,斯德哥尔摩402例)。
- 采用logistic回归开发模型,内部验证用bootstrapping,并在外部验证队列中评估性能。
主要发现
- 668例患者中173例(25.9%)发生CR-POPF,定义依据2016年国际胰腺外科研究组标准。
- 最终模型包含三个术前变量:横断部位(颈部 vs 体/尾部)、横断处胰腺厚度和糖尿病。
- 内部验证后AUROC为0.904(95% CI 0.855—0.949),外部验证后AUROC为0.798(95% CI 0.748—0.848)。
- 外部验证校准斜率0.719,截距0.192。
- 验证队列定义四组风险:低危(低于5%)、中危(至少5%但低于30%)、高危(至少30%但低于75%)、极高危(75%或以上),CR-POPF发生率分别为8.7%(11/126)、22.0%(36/164)、63%(57/91)和81%(17/21)。
关键数值与推荐
- CR-POPF定义采用2016年国际胰腺外科研究组标准。
- 风险分组阈值:低危低于5%,中危至少5%但低于30%,高危至少30%但低于75%,极高危75%或以上。
临床怎么用
- 术前可用DISPAIR评分评估远端胰腺切除术后CR-POPF风险,辅助手术决策和术后管理分层。
- 高危和极高危患者可考虑加强围术期管理或调整手术策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Highly utilized risk scores for clinically relevant postoperative pancreatic fistula (CR-POPF) have guided clinical decision-making in pancreatoduodenectomy. However, none has been successfully developed for distal pancreatectomy. This study aimed to develop and validate a new fistula risk score for distal pancreatectomy. METHODS: Patients undergoing distal pancreatectomy at Helsinki University Hospital, Finland from 2013 to 2021, and at Karolinska University Hospital, Sweden, from 2010 to 2020, were included retrospectively. The outcome was CR-POPF, according to the 2016 International Study Group of Pancreatic Surgery definition. Preoperative clinical demographics and radiological parameters such as pancreatic thickness and duct diameter were measured. A logistic regression model was developed, internally validated with bootstrapping, and the performance assessed in an external validation cohort. RESULTS: Of 668 patients from Helsinki (266) and Stockholm (402), 173 (25.9 per cent) developed CR-POPF. The final model consisted of three variables assessed before surgery: transection site (neck versus body/tail), pancreatic thickness at transection site, and diabetes. The model had an area under the receiver operating characteristic curve (AUROC) of 0.904 (95 per cent c.i. 0.855 to 0.949) after internal validation, and 0.798 (0.748 to 0.848) after external validation. The calibration slope and intercept on external validation were 0.719 and 0.192 respectively. Four risk groups were defined in the validation cohort for clinical applicability: low (below 5 per cent), moderate (at least 5 but below 30 per cent), high (at least 30 but below 75 per cent), and extreme (75 per cent or more). The incidences in these groups were 8.7 per cent (11 of 126), 22.0 per cent (36 of 164), 63 per cent (57 of 91), and 81 per cent (17 of 21) respectively. CONCLUSION: The DISPAIR score after distal pancreatectomy may guide decision-making and allow a risk-adjusted outcome comparison for CR-POPF.
引用
- Bonsdorff A, Ghorbani P, Helanterä I, et al. Development and external validation of DISPAIR fistula risk score for clinically relevant postoperative pancreatic fistula risk after distal pancreatectomy. Br J Surg. 2022. PMID: 35983583. doi:10.1093/bjs/znac266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。